Search clinical trials for: BMN 701

Total 5704 results

BioMarin Pharmaceutical

Completed

Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease

Pompe Disease

United States, United Kingdom, France, Australia, Germany
BioMarin Pharmaceutical

Terminated

Extension Study for Patients Who Have Participated in a BMN 701 Study

Pompe Disease

United States, United Kingdom, Australia, France, Germany, New Zealand
BioMarin Pharmaceutical

Terminated

BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)

Late-onset Pompe Disease

United States, United Kingdom, Germany, France, Italy, Portugal, Belgium, Netherlands
M.D. Anderson Cancer Center

Recruiting

AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer

Adenoid Cystic Carcinoma | Metastatic Adenoid Cystic Carcinoma

United States
University of Nebraska
BioMimetix JV, LLC

Recruiting

Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001

Rectal Cancer

United States
NewG Lab Pharma

Active, not recruiting

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Fibrolamellar Carcinoma

Korea, Republic of
Lumen Bioscience, Inc.

Completed

A Study to Determine the Tolerability of Intranasal LMN-301

COVID-19

Australia
Lumen Bioscience, Inc.

Completed

Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies

C. Diff. Infections

Australia
Bright Minds Biosciences Pty Ltd

Completed

A 3-Part Study to Evaluate the Safety, Tolerability, PK, and Food Effect of BMB-101 in Healthy Volunteers

Healthy

Australia
MediciNova

Completed

Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis

Interstitial Cystitis

United States
Allyx Therapeutics
Michael J. Fox Foundation for Parkinson's Research

Recruiting

A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's

Parkinson Disease

United States
NICHD Neonatal Research Network
National Center for Research Resources (NCRR)

Completed

Trial of Aggressive Versus Conservative Phototherapy in Infants <1,000 Grams Birth Weight (Phototherapy)

Hyperbilirubinemia, Neonatal | Jaundice, Neonatal | Infant, Small for Gestational Age | Infant, Premature | Infant, Low Birth Weight | Infant, Newborn

United States
Microbion Corporation
University of Pennsylvania; University of California, San Francisco; Medpace,... and other collaborators

Completed

Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites

Bacterial Infection

United States
Cephalon

Completed

Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis

Psoriasis

United States
Building Block Nutritionals, LLC
Paidion Research, Inc.

Completed

Growth and Safety Study of an Infant Formula for Healthy Term Infants

Infant Development

United States
Microbion Corporation

Completed

A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI

Diabetic Foot Infection

United States
Cephalon

Completed

Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation

Leukemia, Myeloid
Ronald Levy
Bristol-Myers Squibb

Completed

SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Extracranial Solid Neoplasm

United States
Axovant Sciences Ltd.

Completed

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

Dementia With Lewy Bodies

United States, Canada, France, Italy, Netherlands, Spain, United Kingdom
MediciNova

Recruiting

MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia

Diabetes Mellitus, Type 2 | Hypertriglyceridemia | Non-Alcoholic Fatty Liver Disease

United States
Axovant Sciences Ltd.

Terminated

Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension

Dementia With Lewy Bodies

United States, Canada, France, Italy, Netherlands, Spain, United Kingdom
EGEN, Inc.

Terminated

A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients

Colorectal Cancer

United States
Terns, Inc.

Completed

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

NASH - Nonalcoholic Steatohepatitis

United States
Aalto University
Turku University Hospital; Helsinki University Central Hospital; Business Finland

Active, not recruiting

The Effects of Videogames on Depression Symptoms and Brain Dynamics

Major Depressive Disorder

Finland
Lumen Bioscience, Inc.

Completed

Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers

Campylobacter Jejuni Infection

Australia
Bright Minds Biosciences Pty Ltd

Not yet recruiting

BMB-101 in Epilepsy With Eyelid Myoclonia (EEM)

Jeavons Syndrome

Australia
Millennium Pharmaceuticals, Inc.

Completed

Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies

Advanced Solid Tumors

United States
TWi Biotechnology, Inc.

Completed

Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy

EGFR Inhibitor-Induced Skin Rash

Taiwan
Terns, Inc.

Not yet recruiting

CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic Phase

United States
Amgen

Available

AMG 701 Expanded Access Program
Amgen

Withdrawn

A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ProxiMMity-1)

Relapsed/Refractory Multiple Myeloma
New Approaches to Neuroblastoma Therapy Consortium
National Cancer Institute (NCI)

Completed

N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma

Neuroblastoma

United States, Canada
Trius Therapeutics LLC

Completed

Microdialysis and Pharmacokinetic Study of TR-701

Healthy

United States
Ronald Levy
National Cancer Institute (NCI)

Active, not recruiting

TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | B-Cell Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
BioMimetix JV, LLC
National Cancer Institute (NCI); Duke Cancer Institute

Terminated

A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy

Multiple Brain Metastases

United States
Ronald Hoffman
National Cancer Institute (NCI); Myeloproliferative Disorders-Research Consortium

Unknown

CEP-701 (Lestaurtinib) in Myelofibrosis

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis

United States
Cephalon

Terminated

Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma

Myeloma

United States
Trius Therapeutics LLC

Completed

Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

Skin Diseases, Infectious | Skin Diseases, Bacterial

United States
BioMimetix JV, LLC
Duke University; University of California, San Francisco

Completed

A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer (BMX-HN)

Head and Neck Cancer

United States
Karen Ballen, MD

Recruiting

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002)

Acute Myeloid Leukemia | Myelofibrosis | Chronic Myelomonocytic Leukemia

United States
Bellicum Pharmaceuticals

Terminated

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Uveal Melanoma

United States
BioMarin Pharmaceutical

Active, not recruiting

A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema (HAErmony-1)

Hereditary Angioedema | HAE

Spain, United States, Australia
Lumen Bioscience, Inc.

Not yet recruiting

LMN-201 for Prevention of C. Difficile Infection Recurrence

Clostridioides Difficile Infection
Corbus Pharmaceuticals Inc.
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Solid Tumor, Adult

United States, Spain, Turkey, United Kingdom
Reveal Pharmaceuticals Inc.
National Cancer Institute (NCI)

Recruiting

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Central Nervous System (CNS) Lesions

United States
BioMarin Pharmaceutical

Recruiting

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Spain, United Kingdom
National Cancer Institute (NCI)

Recruiting

Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

Neuroendocrine Tumors | Carcinoma, Neuroendocrine | Neuroendocrine Carcinomas | Carcinoma, Adrenal Cortical | Carcinoma, Adrenocortical

United States
Cephalon

Completed

Study of CEP-701 in Treatment of Prostate Cancer

Prostate Cancer

United States
University of Connecticut
United States Department of Defense; AMP Human; Park City, UT

Completed

The Effect of AMP Human Sodium Bicarbonate Lotion on Hydration (AMPlify)

Cognitive Change | Electrolyte and Fluid Balance Conditions | Fluid Retention | Heat Exposure | Fluid Loss | Hyperhydration | Sodium Retention

United States
BioMarin Pharmaceutical

Terminated

Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

Netherlands, Belgium, Italy, Sweden

Search clinical trials for: BMN 701

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations